Tumor Biology

, Volume 36, Issue 5, pp 3465–3470 | Cite as

Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells

  • Yinghua LiEmail author
  • Haifeng Gao
  • Yan Wang
  • Chaoyang Dai
Research Article


The study aims to investigate the relationship between nuclear factor (nuclear factor kappa B (NF-κB)) viability and lactacystin-mediated cell apoptosis in gastric cancer cells. Two gastric cancer cell lines (MKN28 and SGC7901) were treated with lactacystin—a proteasome inhibitor for 24 h. The cell viability, toxicity, and death were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. DNA binding viability of NF-κB and caspase-3 viability were analyzed by ELISA; the expression of p65 NF-κB nuclear protein was detected by immunocytochemistry and Western blot. Lactacystin reduced DNA binding viability of NF-κB (t = 3.0,P = 0.013) and the NF-κB viability (compared to the 5, 10 μmol/L MKN28 cell (p53 mutant) line, P < 0.001) and the expression of p65 NF-κB nuclear protein decreased parallelled to concentrations of lactacystin in MKN28 cell line, while without obvious effects on NF-κB viability in SGC7901 cell line (P = 0.381), while the viability of caspase-3 increased also along with the raising of lactacystin concentrations (compared to control, 5 μmol/L: SGC7901 cell line P = 0.029, MKN28 cell line P < 0.001; 10 μmol/L: SGC7901 cell line, P < 0.001, MKN28 cell line, P < 0.001). It was concluded that lactacystin had diversified killing effects on gastric cancer cells. The mechanism may be related to induce the apoptosis by downregulation of nuclear factor kappa B viability. There may be additional cell survival/death pathway in SGC7901 gastric cancer cells.


Gastric cancer Lactacystin Nuclear factor kappa B NF-κB Caspase-3 


Conflicts of interest



  1. 1.
    Liu W, Yang Q, Liu B, Zhu Z. Serum proteomics for gastric cancer. Clin Chim Acta. 2014;431:179–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Fan XM, Wong BCY, Wang WP, Zhou XM, Cho CH, Yuen ST, et al. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer. 2001;93:481–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Cohen G. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1–16.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008;68:7283–92.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D’Alessandro N, et al. Novel combination of celecoxib and proteasome inhibitor mg132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 2010;9:1399–410.CrossRefPubMedGoogle Scholar
  6. 6.
    Rastogi N, Mishra DP. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012;26:7–26.Google Scholar
  7. 7.
    Slater E, Waldmann J, López C, Matthäi E, Fendrich V, Bartsch D. Pancreatic neuroendocrine tumors are characterized by loss of noxa expression that can be recovered by the proteasome inhibitor bortezomib. J Cancer Ther. 2013;4:28.CrossRefGoogle Scholar
  8. 8.
    Budunova I. Differential targeting of androgen and glucocorticoid receptors induces er stress and apoptosis in prostate cancer cells. Cell Cycle. 2012;11:395–406.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen J, Giridhar KV, Zhang L, Xu S, Wang QJ. A protein kinase c/protein kinase d pathway protects lncap prostate cancer cells from phorbol ester-induced apoptosis by promoting erk1/2 and nf-κb activities. Carcinogenesis. 2011;32:1198–206.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV. Targeting transcription factor nfκb: comparative analysis of proteasome and ikk inhibitors. Cell Cycle. 2009;8:1559–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the nf-κb1 precursor protein and the activation of nf-κb. Cell. 78:773–85.Google Scholar
  12. 12.
    Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting nf-κb activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (BBA) - Gene Regul Mech. 2010;1799:775–87.CrossRefGoogle Scholar
  14. 14.
    Leotoing L, Chereau F, Baron S, Hube F, Valencia H, Bordereaux D, et al. A20-binding inhibitor of nuclear factor-kappab (nf-kappab)-2 (abin-2) is an activator of inhibitor of nf-kappab (ikappab) kinase alpha (ikkalpha)-mediated nf-kappab transcriptional activity. J Biol Chem. 2011;286:32277–88.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cho W-R, Yoon H. Apple extracts attenuate tumor necrosis factor-α-induced nuclear factor-κb activation by inhibiting iκb kinase and proteasome in a549 human non-small lung carcinoma cells. Food Sci Biotechnol. 2012;21:1203–8.CrossRefGoogle Scholar
  16. 16.
    White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996;10:1–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Singh S, Khar A. Activation of nfκb and ub-proteasome pathway during apoptosis induced by a serum factor is mediated through the upregulation of the 26 s proteasome subunits. Apoptosis. 2006;11:845–59.CrossRefPubMedGoogle Scholar
  18. 18.
    Ahn J, Lee H, Kim S, Park J, Ha T. The anti-obesity effect of quercetin is mediated by the ampk and mapk signaling pathways. Biochem Biophys Res Commun. 2008;373:545–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Calvaruso G, Giuliano M, Portanova P, De Blasio A, Vento R, Tesoriere G. Bortezomib induces in hepg2 cells iκbα degradation mediated by caspase-8. Mol Cell Biochem. 2006;287:13–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. Mir‐15b and mir‐16 modulate multidrug resistance by targeting bcl2 in human gastric cancer cells. Int J Cancer. 2008;123:372–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J, et al. Inhibition of prl-3 gene expression in gastric cancer cell line sgc7901 via microrna suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun. 2006;348:229–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, et al. Cellular prion protein promotes proliferation and g1/s transition of human gastric cancer cells sgc7901 and ags. FASEB J. 2007;21:2247–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Sun L, Wang X. Effects of allicin on both telomerase activity and apoptosis in gastric cancer sgc-7901 cells. World J Gastroenterol. 2003;9:1930–4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yinghua Li
    • 1
    Email author
  • Haifeng Gao
    • 2
  • Yan Wang
    • 3
  • Chaoyang Dai
    • 1
  1. 1.Department of OncologyThe Second Affiliated Hospital of Dalian Medical UniversityDalianChina
  2. 2.Department of UrologyThe Dalian Central HospitalDalianChina
  3. 3.Department of the Central LaboratoryThe Second Affiliated Hospital of Dalian Medical UniversityDalianChina

Personalised recommendations